Zydus And Synthon Sign US Ibrance Generic Deal With Potential Exclusivity

Synthon And Pfizer Settle US Patent Infringement Claims Over $3.1bn Palbociclib Brand

 
• By Urtė Fultinavičiūtė

Zydus and Synthon’s entry into a high-value collaboration on palbociclib tablets is amped up with a paragraph IV certification, which may lead to a 180-day market exclusivity.

Deal handshake agreement document
The paragraph IV certification may grant a six-month market exclusivity • Source: Shutterstock

More from Deals

More from Business